This guidance provides recommendations to industry regarding postmarketing adverse event reporting for drugs, biologics, medical devices, and dietary supplements during a pandemic.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/3Wvkeni
No comments:
Post a Comment